PRX003 is a monoclonal antibody under development by Prothena for the possible treatment of inflammatory diseases. It is currently being tested in patients with multiple sclerosis (MS).

Immune cells release cytokines that can trigger inflammation and are central to many inflammatory diseases. An MCAM (melanoma cell adhesion molecule) binds to a partner molecule the blood stream then then allows it to infiltrate adjacent tissues, leading to inflammation.

In healthy people, the blood-brain barrier prevents immune cells (lymphocytes) from entering the central nervous system. In people with MS, two types of lymphocytes, CD4 and CD8, find a way to cross the barrier. They then destroy the myelin sheath that protects neurons, resulting in brain lesions.

MCAM may play a crucial role in MS because it is necessary for the migration of both CD4 and CD8 lymphocytes across the blood-brain barrier. Blocking MCAM may delay the onset of MS and significantly slow its progression.

PRX003 binds to MCAM, blocks the route of inflammation, and prevents the migration of CD4 and CD8 lymphocytes into the brain tissue.

In March, Prothena completed a single ascending dose study of PRX003 in healthy participants (NCT02458677). All doses of PRX003 were reported as safe and tolerated following a single infusion up to 30 mg/kg dose. The results showed that PRX003 administration led to more than 95 percent MCAM neutralization.

Adverse effects reported were headache, balance disorder, seasonal allergies, and viral upper respiratory tract infection in 5 percent of participants.

A Phase 1b clinical study of PRX003 in people with psoriasis (NCT02630901) is ongoing.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Cometh the Hour, Cometh the Woman

In this case, the woman in question was yet again my wife, Jane. The hour in question was 4 p.m. on my usual day of writing. But on this day, writing had to be forgotten until a stint later at night (yawn). I had an entertainment Zoom call to partake in. Then dinner of an […]

It’s Disability Pride Month — But Not for Me

July is Disability Pride Month. Now, don’t slam me right away for writing this, but I don’t think we need a month highlighting disability pride — just like I don’t think we need a month in October spotlighting that we have rare diseases, especially because to me, multiple sclerosis isn’t rare. (More than 2.3 million […]

Trial of Cannabis Derivatives in Treating MS Spasticity to Open in Canada

The Multiple Sclerosis Society of Canada and its partner, the Canadian Institutes of Health Research (CIHR), have invested CA$1.5 million to open a clinical trial that will investigate the potential of two cannabis derivatives — cannabidiol (CBD) and tetrahydrocannabinol (THC) — in treating spasticity (muscle stiffness) and other symptoms of multiple sclerosis (MS). The money, worth about […]

MS Imaging Startup Among 8 Minority-owned Firms Earning Investment

JuneBrain, a startup company that is developing a wearable head imaging device that enables multiple sclerosis (MS) patients to remotely monitor their disease activity and treatment response, has received a $50,000 investment through TEDCO’s Builder Fund, the investor announced. MS is caused by inflammation in the brain, which causes damage to brain structures. This damage is […]

B-Cells Infected by Epstein-Barr Virus Linked to MS Relapse Risk in Study

Immune B-cells that proliferate unchecked when infected by the Epstein-Barr virus (EBV) appear to increase the risk of relapses in patients with multiple sclerosis (MS), a mouse study suggests. The study, “Epstein Barr virus‐immortalized B lymphocytes exacerbate experimental autoimmune encephalomyelitis in xenograft mice,” was published in the Journal of Medical Virology. EBV, also known as human […]

Disability Builds in Relapsing MS in Ways Not Tied to Relapses, Analysis Finds

Disability appears to mostly accumulate in people with relapsing forms of multiple sclerosis (MS) in a progressive manner — rather than being due to relapses, a pooled analysis of patients in two Ocrevus (ocrelizumab) clinical trials shows. These findings, indicating that disease progression underlies relapsing MS as well, “challenge the current clinical distinction of relapsing […]

BMS, Dragonfly Working on Immune System-targeting Therapies for MS

Dragonfly Therapeutics and Bristol Myers Squibb (BMS) announced an expanded partnership focused on discovering and developing treatment candidates for multiple sclerosis (MS) and neuroinflammation targets. The companies have been working together in therapy research and development for cancer and autoimmune diseases using Dragonfly’s proprietary immunotherapy targeting platform. Under the expanded agreement, Dragonfly is giving BMS the […]

Switch from Tysabri to Ocrevus Seen as Safe, Effective in RRMS Patients in Small Study

Switching to Ocrevus (ocrelizumab) within a relatively short period is a safe and effective option for people with relapsing-remitting multiple sclerosis (RRMS) who stop treatment with Tysabri (natalizumab), a small and retrospective analysis suggests. With a median washout period of six weeks between therapies, the 28 patients in this study had no relapses and there were no reports […]

Study: Mavenclad Shows Long-term Effectiveness at Preventing MS Relapses, Disease Progression

Mavenclad (cladribine) prevents relapses and disease progression in more than half of patients with relapsing forms of multiple sclerosis (MS) for at least five years after the last dose, according to a real-life study from Italy. These findings, based on real-world data from Italian MS patients previously treated with Mavenclad in clinical trials, support the therapy’s long-term […]